Immunological approaches have been used to demonstrate the presence of advanced glycation endproducts (AGEs) in several human and experimental animal tissues. We previously prepared polyclonal and monoclonal anti-AGE antibodies by immunizing AGE-modified proteins such as BSA and RNase. Although these antibodies contributed to demonstrate the presence of AGE-modified protein in vivo, the epitope structure of these antibodies had not been identified. We subsequently prepared several antibodies against AGE structures such as pentosidine, pyrraline, 3-deoxyglucosone imidazolone and N ε -(carboxyethyl)lysine by immunizing single AGE structures. These structure-specific antibodies have greatly helped broaden our understanding of AGE structures in aging and age-enhanced disease process. Monoclonal anti-AGE antibody is also used for the identification of major AGE structures in some pathological tissues, such as human atherosclerosis lesions. Based on the strategy, we successfully identified a novel AGE structure named glycolaldehyde-pyridine, which is the major antigenic AGE derived from glycolaldehyde. Therefore a monoclonal antibody library for AGE structures has served an important role in the elucidation of the biological significance of AGE.
Anti-AGE (advanced glycation end-product) antibodies
Recent studies have suggested the potential role of AGE in atherosclerosis, aging and diabetic complications. Immunological studies using antibodies specific for AGE-modified protein have confirmed their presence in vivo. Using AGEmodified BSA (AGE-BSA) as an antigen, we have previously prepared a monoclonal anti-AGE antibody (6D12) in mice, as well as a polyclonal anti-AGE antibody in rabbits [1] . These antibodies were classified into three groups. Group I was specific for N ε -(carboxymethyl)lysine (CML), whereas both groups II and III were unreactive to CML. The epitope of group II was formed much earlier than that of group III during incubation of BSA with glucose in vitro [2] . Our previous study also identified the epitope of 6D12 as CML [3] , the carbonyl group of which played an important role in recognition by the antibody. Furthermore, since approx. 30% of the antibody in our polyclonal anti-AGE antibody was directed against CML, CML is a major immunological epitope in proteins modified with AGE. Accumulation of CML was detected in the normal aging process [4] , as well as in the pathogenesis of several age-enhanced diseases such as diabetic nephropathy [5] [6] [7] , retinopathy [8] , atherosclerosis [9] [10] [11] and haemodialysis-associated amyloidosis [12] . Considered together, these studies strongly suggest an Key words: anti-AGE antibody, N ε -(carboxymethyl)lysine, N ε -(carboxyethyl)lysine, glycolaldehyde-pyridine, pentosidine, pyrraline. Abbreviations used: AGE, advanced glycation end-product; CEL, N ε -(carboxyethyl)lysine; CML, N ε -(carboxymethyl)lysine; 3-DG, 3-deoxyglucosone; GA, glycolaldehyde; HSA, human serum albumin; KLH, keyhole limpet haemocyamin. 1 To whom correspondence should be addressed (e-mail horiuchi@gpo.kumamoto-u.ac.jp).
association between CML and the development of diabetic complications. In immunochemistry, the heat-induced epitope retrieval technique is extensively used with formalinfixed paraffin-embedded tissue sections. However, we demonstrated that CML generated by heating, directly from oxidative cleavage of Amadori products or via several reactive aldehydes might serve as a false-positive for results observed in the immunohistochemical study with the anti-CML antibody after antigen retrieval by heating [13] .
The 6D12 antibody was also used to demonstrate the formation pathway of CML. CML is generated through three pathways in vitro: by oxidative cleavage of Amadori products, cleavage of the Schiff's base through the Namiki pathway and autoxidation of glucose through glyoxal. Among these, oxidative cleavage of Amadori products into CML is considered a major pathway in vivo, because this pathway mostly progresses under physiological phosphate concentrations. We previously demonstrated that the hydroxyl radical, which was generated by the Fenton reaction between Fe 2+ and Amadori-derived hydrogen peroxide, plays an important role in the formation of CML from glycated human serum albumin (HSA) in vitro [14] . Furthermore, we also found that CML was readily formed on treatment of glycated HSA with peroxynitrite (ONOO − ) and also on exposure of the protein to ONOO − -treated glucose [15] (Scheme 1). In both cases, the yield of CML increased with increasing concentrations of ONOO − . Since the rate constant for ONOO − formation (7 × 10 9 M −1 · s −1 ) is 1000-fold higher than that of the hydroxyl radical, and the half-life of ONOO − is 10 9 times longer than that of hydroxyl radical under physiological conditions, it is highly likely that the formation of CML in vivo is mediated by ONOO − rather than by a hydroxyl radical. 
Structure-specific antibodies
We also prepared structure-specific (known epitope) anti-AGE antibodies by immunizing single AGE structures, such as N ε -(carboxyethyl)lysine (CEL) [16, 17] , pentosidine [18] [19] [20] , pyrraline [21, 22] and 3-DG (3-deoxyglucosone)-imidazolone [19, 21] . For instance, splenic lymphocytes separated from CEL-BSA-immunized Balb/c mice were fused to myeloma P3U1 cells and one cell line, named KNH-30, positive to CEL-RNase but negative to CMLRNase, was selected through successive subcloning. The immunohistochemical investigation revealed that positive reactivity for KNH-30 was found markedly in the brain and spinal cord of rat fetuses when compared with those of postnatal rats. These results strongly suggest that CEL accumulation in tissues and cells occurs not only during aging, but also from an early stage of ontogeny [16] .
In order to obtain monoclonal anti-pentosidine antibody, diacetylpentosidine-conjugated HSA was prepared by the EDC [1-ethyl-3-(3-dimethylaminopropyl)carbodi-imide hydrochloride] method and immunized in Balb/c mice. One cell line, named 1C12, which was found to be positive for pentosidine-HSA and pentosidine-KLH (keyhole limpet haemocyanin) was selected through successive subcloning. Although N-monomethyl-arginine and N-propylpyridinium bromide did not react with 1C12, 2-aminobenzimidazole was significantly recognized by the antibody in a fashion similar to that of free pentosidine, indicating that 1C12 recognizes the nine-member heterocyclic ring structure of pentosidine, which is common to both pentosidine and 2-aminobenzimidazole [18] . The pentosidine concentration produced by in vitro incubation of plasma obtained from uraemic patients was reported to be higher than in normal plasma, indicating that uraemic plasma contains an enhancer(s) for pentosidine formation [23] . Our preliminary study using 1C12 identified creatine as the most effective enhancer for pentosidine formation. Our subsequent study, however, demonstrated that pentosidine-like structure in which the arginine residue was replaced by creatine was generated during the incubation of lysine with ribose in the presence of creatine. This novel AGE structure, named C-pentosidine (creatine-derived pentosidine), was detected by HPLC in the plasma of patients with haemodialysis. This study indicates that creatine plays a direct role as a protein modifier in C-pentosidine formation [18] . In a similar fashion, we also prepared antibodies against 3-DG-imidazolone and pyrraline, and these were used to demonstrate the presence of their structures in vivo (Table 1) .
Finding a novel biological marker
Monoclonal antibodies are also used to identify novel biological markers in pathological lesions. Products of nonenzymatic reactions, such as 3-DG, glyoxal and methylglyoxal, are formed in tissue proteins in vivo and are considered to be precursors of AGEs. In a parallel pathway involving both enzymatic and non-enzymatic reactions during inflammation, leucocytes are activated to secrete myeloperoxidase, which mediates the formation of hypochlorous acid (HOCl) from hydrogen peroxide and chloride [24] . Aldehydes such as glycolaldehyde (GA), which is formed by reaction of HOCl with serine, then react to form chemical modifications in protein. GA is known to react with protein amino residues to give brown-coloured cross-linked structures [25] . A recent study demonstrated that the reaction of myeloperoxidasederived GA with RNase led to CML, indicating that CML is formed in GA-modified protein [26] . However, since CML is also formed by the Maillard reaction pathways, such as oxidative cleavage of Amadori product, Schiff base formation and autoxidation of glucose via glyoxal, CML is not a specific marker for myeloperoxidase-induced protein modification in vivo. Therefore, in order to obtain a specific marker for myeloperoxidase-induced protein modification in vivo, it is requisite to identify a GA-protein adduct(s) other than CML. Demonstration of such a specific marker in atherosclerotic lesions would establish a role for the myeloperoxidase system in chemical modification of proteins during atherogenesis. To this end, monoclonal (GA5 and 1A12) and polyclonal (non-CML-GA) antibodies specific for GA-modified proteins were prepared [27] . These antibodies specifically reacted with GA-and with hypochlorous acidmodified BSA, but not with BSA modified by other aldehydes such as glucose, glyoxal, methylglyoxal and 3-DG, indicating that the epitope of these antibodies could be a specific marker for GA-modified protein. By HPLC purification, GA5-reactive compound was isolated and its chemical structure was characterized as 3-hydroxy-4-hydroxymethyl-1-(5-amino-5-carboxypentyl) pyridinium cation. This compound, named GA-pyridine, was recognized both by 1A12 and non-CML-GA, indicating that GA-pyridine is an important antigenic structure in GA-modified proteins. Immunohistochemical studies with GA5 demonstrated the accumulation of GA-pyridine in the cytoplasm of foam cells and extracellularly in the central region of atheroma in human atherosclerotic lesions [27] . These results suggest that myeloperoxidase-mediated protein modification via GA may contribute to atherogenesis. Taken together, antibody libraries for AGE structures are important tools not only for the demonstration of the presence of known AGE structures, but also to identify novel AGE structures in vitro and in vivo.
